SIT1 transporter as a potential novel target in treatment of COVID-19

{ 'indexed': { 'date-parts': [[2021, 12, 31]], 'date-time': '2021-12-31T05:57:42Z', 'timestamp': 1640930262401}, 'reference-count': 92, 'publisher': 'Walter de Gruyter GmbH', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'published-print': {'date-parts': [[2021, 1, 1]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Studies published earlier this year demonstrated the association of ' 'the solute carrier <jats:italic>SLC6A20</jats:italic> gene with the risk and severity of ' 'COVID-19. The <jats:italic>SLC6A20</jats:italic> protein product (Sodium-dependent Imino ' 'Transporter 1 (SIT1)) is involved in the transport of amino acids, including glycine. Here we ' 'summarized the results of recent studies demonstrating the interaction of SIT1 with the ACE2 ' 'receptor for SARS-CoV-2 as well as an observed association of ' '<jats:italic>SLC6A20</jats:italic> with the risk and traits of Type 2 diabetes (T2D). ' 'Recently, it was also proposed that <jats:italic>SLC6A20</jats:italic> represents the novel ' 'regulator of glycine levels and that glycine has beneficial effects against the ' 'proinflammatory cytokine secretion induced by SARS-CoV-2 infection. Ivermectin, as a partial ' 'agonist of glycine-gated chloride channels, was also recently suggested to interfere with the ' 'COVID-19 cytokine storm by inducing the activation of glycine receptors. Furthermore, plasma ' 'glycine levels are found to be decreased in diabetic patients. Thus, further clinical trials ' 'are warranted to confirm the potential favorable effects of targeting the SIT1 transporter ' 'and glycine levels in the treatment of COVID-19, particularly for the severe case of disease ' 'associated with hyperglycemia, inflammation, and T2D. These findings suggest that SIT1 may ' 'potentially represent one of the missing pieces in the complex puzzle observed between these ' 'two pandemic diseases and the potential novel target for their efficient treatment.</jats:p>', 'DOI': '10.1515/bmc-2021-0017', 'type': 'journal-article', 'created': { 'date-parts': [[2021, 12, 30]], 'date-time': '2021-12-30T13:00:50Z', 'timestamp': 1640869250000}, 'page': '156-163', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['SIT1 transporter as a potential novel target in treatment of COVID-19'], 'prefix': '10.1515', 'volume': '12', 'author': [ { 'given': 'Sabina', 'family': 'Semiz', 'sequence': 'first', 'affiliation': [ { 'name': 'College of Medicine and Health Sciences , Khalifa University , ' 'Abu Dhabi , United Arab Emirates ; Association South East ' 'European Network for Medical Research-SOVE , E-mail: ' 'sabina.semiz@ku.ac.ae'}]}], 'member': '374', 'published-online': {'date-parts': [[2021, 12, 30]]}, 'reference': [ { 'key': '2021123018400923816_j_bmc-2021-0017_ref_001', 'doi-asserted-by': 'crossref', 'unstructured': 'Kasela S, Daniloski Z, Bollepalli S, Jordan TX, tenOever BR, Sanjana NE, ' 'et al. Integrative approach identifies SLC6A20 and CXCR6 as putative ' 'causal genes for the COVID-19 GWAS signal in the 3p21.31 locus. Genome ' 'Biol. 2021 Aug;22(1):242.', 'DOI': '10.1186/s13059-021-02454-4'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_002', 'doi-asserted-by': 'crossref', 'unstructured': 'Yao Y, Ye F, Li K, Xu P, Tan W, Feng Q, et al. Genome and epigenome ' 'editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus ' 'associated with severe COVID-19. Signal Transduct Target Ther. 2021 ' 'Feb;6(1):85.', 'DOI': '10.1038/s41392-021-00519-1'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_003', 'doi-asserted-by': 'crossref', 'unstructured': 'Bae M, Roh JD, Kim Y, Kim SS, Han HM, Yang E, et al. SLC6A20 ' 'transporter: a novel regulator of brain glycine homeostasis and NMDAR ' 'function. EMBO Mol Med. 2021 Feb;13(2):e12632.', 'DOI': '10.15252/emmm.202012632'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_004', 'doi-asserted-by': 'crossref', 'unstructured': 'Takanaga H, Mackenzie B, Suzuki Y, Hediger MA. Identification of ' 'mammalian proline transporter SIT1 (SLC6A20) with characteristics of ' 'classical system imino. J Biol Chem. 2005 Mar;280(10):8974–84.', 'DOI': '10.1074/jbc.M413027200'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_005', 'doi-asserted-by': 'crossref', 'unstructured': 'Perlot T, Penninger JM. ACE2 - from the renin-angiotensin system to gut ' 'microbiota and malnutrition. Microbes Infect. 2013 Nov;15(13):866–73.', 'DOI': '10.1016/j.micinf.2013.08.003'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_006', 'doi-asserted-by': 'crossref', 'unstructured': 'Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando ' 'J, et al. Human intestine luminal ACE2 and amino acid transporter ' 'expression increased by ACE-inhibitors. Amino Acids. 2015 ' 'Apr;47(4):693–705.', 'DOI': '10.1007/s00726-014-1889-6'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_007', 'doi-asserted-by': 'crossref', 'unstructured': 'Camargo SM, Vuille-Dit-Bille RN, Meier CF, Verrey F. ACE2 and gut amino ' 'acid transport. Clin Sci (Lond). 2020 Nov;134(21):2823–33.', 'DOI': '10.1042/CS20200477'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_008', 'doi-asserted-by': 'crossref', 'unstructured': 'Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, ' 'et al.; Severe Covid-19 GWAS Group. Genomewide Association Study of ' 'Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020 ' 'Oct;383(16):1522–34.', 'DOI': '10.1056/NEJMoa2020283'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_009', 'doi-asserted-by': 'crossref', 'unstructured': 'Wang A, Chiou J, Poirion OB, Buchanan J, Valdez MJ, Verheyden JM, et ' 'al.; NHLBI LungMap Consortium. Single-cell multiomic profiling of human ' 'lungs reveals cell-type-specific and age-dynamic control of SARS-CoV2 ' 'host genes. eLife. 2020 Nov;9:9.', 'DOI': '10.7554/eLife.62522'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_010', 'doi-asserted-by': 'crossref', 'unstructured': 'Camargo SM, Singer D, Makrides V, Huggel K, Pos KM, Wagner CA, et al. ' 'Tissue-specific amino acid transporter partners ACE2 and collectrin ' 'differentially interact with hartnup mutations. Gastroenterology. 2009 ' 'Mar;136(3):872–82.', 'DOI': '10.1053/j.gastro.2008.10.055'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_011', 'doi-asserted-by': 'crossref', 'unstructured': 'Kaur U, Acharya K, Mondal R, Singh A, Saso L, Chakrabarti S, et al. ' 'Should ACE2 be given a chance in COVID-19 therapeutics: A ' 'semi-systematic review of strategies enhancing ACE2. Eur J Pharmacol. ' '2020 Nov;887:173545.', 'DOI': '10.1016/j.ejphar.2020.173545'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_012', 'doi-asserted-by': 'crossref', 'unstructured': 'Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020 ' 'Sep;39:101044.', 'DOI': '10.1016/j.molmet.2020.101044'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_013', 'doi-asserted-by': 'crossref', 'unstructured': 'Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al.; China ' 'Medical Treatment Expert Group for COVID-19. Comorbidity and its impact ' 'on 1590 patients with COVID-19 in China: a nationwide analysis. Eur ' 'Respir J. 2020 May;55(5):2000547.', 'DOI': '10.1183/13993003.01227-2020'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_014', 'doi-asserted-by': 'crossref', 'unstructured': 'Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson ' 'KW, et al.; the Northwell COVID-19 Research Consortium. Presenting ' 'Characteristics, Comorbidities, and Outcomes Among 5700 Patients ' 'Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 ' 'May;323(20):2052–9.', 'DOI': '10.1001/jama.2020.6775'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_015', 'doi-asserted-by': 'crossref', 'unstructured': 'Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest ' 'outcomes among patients with COVID-19 pneumonia in Wuhan, China. ' 'Resuscitation. 2020 Jun;151:18–23.', 'DOI': '10.1016/j.resuscitation.2020.04.005'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_016', 'doi-asserted-by': 'crossref', 'unstructured': 'Lim ZJ, Ponnapa Reddy M, Curtis JR, Afroz A, Billah B, Sheth V, et al. A ' 'Systematic Review of the Incidence and Outcomes of In-Hospital Cardiac ' 'Arrests in Patients With Coronavirus Disease 2019. Crit Care Med. 2021 ' 'Jun;49(6):901–11.', 'DOI': '10.1097/CCM.0000000000004950'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_017', 'doi-asserted-by': 'crossref', 'unstructured': 'Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: ' 'A systematic review and current update. Acta Neurol Scand. 2020 ' 'Jul;142(1):14–22.', 'DOI': '10.1111/ane.13266'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_018', 'doi-asserted-by': 'crossref', 'unstructured': 'O’Loughlin L, Alvarez Toledo N, Budrie L, Waechter R, Rayner J. A ' 'Systematic Review of Severe Neurological Manifestations in Pediatric ' 'Patients with Coexisting SARS-CoV-2 Infection. Neurol Int. 2021 ' 'Aug;13(3):410–27.', 'DOI': '10.3390/neurolint13030041'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_019', 'doi-asserted-by': 'crossref', 'unstructured': 'Tufano A, Rendina D, Abate V, Casoria A, Marra A, Buonanno P, et al. ' 'Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A ' 'Systematic Review with Meta-Analysis. J Clin Med. 2021 Oct;10(21):4925.', 'DOI': '10.3390/jcm10214925'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_020', 'doi-asserted-by': 'crossref', 'unstructured': 'Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from ' 'pathophysiology to clinical management. Nat Rev Endocrinol. 2021 ' 'Jan;17(1):11–30.', 'DOI': '10.1038/s41574-020-00435-4'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_021', 'doi-asserted-by': 'crossref', 'unstructured': 'Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri ' 'F. Inflamm-aging: why older men are the most susceptible to SARS-CoV-2 ' 'complicated outcomes. Cytokine Growth Factor Rev. 2020 Jun;53:33–7.', 'DOI': '10.1016/j.cytogfr.2020.04.005'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_022', 'doi-asserted-by': 'crossref', 'unstructured': 'Prattichizzo F, Sabbatinelli J, de Candia P, Olivieri F, Ceriello A. ' 'Tackling the pillars of ageing to fight COVID-19. Lancet Healthy Longev. ' '2021 Apr;2(4):e191.', 'DOI': '10.1016/S2666-7568(21)00053-2'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_023', 'doi-asserted-by': 'crossref', 'unstructured': 'Schlesinger S, Neuenschwander M, Lang A, Pafili K, Kuss O, Herder C, et ' 'al. Risk phenotypes of diabetes and association with COVID-19 severity ' 'and death: a living systematic review and meta-analysis. Diabetologia. ' '2021 Jul;64(7):1480–91.', 'DOI': '10.1007/s00125-021-05458-8'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_024', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhu Z, Mao Y, Chen G. Predictive value of HbA1c for in-hospital adverse ' 'prognosis in COVID-19: A systematic review and meta-analysis. Prim Care ' 'Diabetes. 2021 Aug;15(6):S1751-9918(21)00130-3. ' 'https://doi.org/10.1016/j.pcd.2021.07.013.', 'DOI': '10.1016/j.pcd.2021.07.013'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_025', 'doi-asserted-by': 'crossref', 'unstructured': 'Yang Y, Cai Z, Zhang J. Hyperglycemia at admission is a strong predictor ' 'of mortality and severe/critical complications in COVID-19 patients: a ' 'meta-analysis. Biosci Rep. 2021 Feb;41(2):BSR20203584. ' 'https://doi.org/10.1042/BSR20203584.', 'DOI': '10.1042/BSR20203584'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_026', 'doi-asserted-by': 'crossref', 'unstructured': 'Lazarus G, Audrey J, Wangsaputra VK, Tamara A, Tahapary DL. High ' 'admission blood glucose independently predicts poor prognosis in ' 'COVID-19 patients: A systematic review and dose-response meta-analysis. ' 'Diabetes Res Clin Pract. 2021 Jan;171:108561.', 'DOI': '10.1016/j.diabres.2020.108561'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_027', 'doi-asserted-by': 'crossref', 'unstructured': 'Chen J, Wu C, Wang X, Yu J, Sun Z. The Impact of COVID-19 on Blood ' 'Glucose: A Systematic Review and Meta-Analysis. Front Endocrinol ' '(Lausanne). 2020 Oct;11:574541.', 'DOI': '10.3389/fendo.2020.574541'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_028', 'doi-asserted-by': 'crossref', 'unstructured': 'Prattichizzo F, de Candia P, Nicolucci A, Ceriello A. Elevated HbA1c ' 'levels in pre-Covid-19 infection increases the risk of mortality: A ' 'sistematic review and meta-analysis. Diabetes Metab Res Rev. 2021 ' 'May;•••:e3476.', 'DOI': '10.1002/dmrr.3476'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_029', 'doi-asserted-by': 'crossref', 'unstructured': 'Ceriello A, Prattichizzo F. Pharmacological management of COVID-19 in ' 'type 2 diabetes. J Diabetes Complications. 2021 Jul;35(7):107927.', 'DOI': '10.1016/j.jdiacomp.2021.107927'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_030', 'doi-asserted-by': 'crossref', 'unstructured': 'Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, ' 'et al. Metformin and risk of mortality in patients hospitalised with ' 'COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021 ' 'Jan;2(1):e34–41.', 'DOI': '10.1016/S2666-7568(20)30033-7'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_031', 'doi-asserted-by': 'crossref', 'unstructured': 'Lalau JD, Al-Salameh A, Hadjadj S, Goronflot T, Wiernsperger N, Pichelin ' 'M, et al.; CORONADO investigators. Metformin use is associated with a ' 'reduced risk of mortality in patients with diabetes hospitalised for ' 'COVID-19. Diabetes Metab. 2021 Sep;47(5):101216.', 'DOI': '10.1016/j.diabet.2020.101216'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_032', 'doi-asserted-by': 'crossref', 'unstructured': 'Li Y, Yang X, Yan P, Sun T, Zeng Z, Li S. Metformin in Patients With ' 'COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne). ' '2021 Aug;8:704666.', 'DOI': '10.3389/fmed.2021.704666'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_033', 'doi-asserted-by': 'crossref', 'unstructured': 'Penlioglou T, Papachristou S, Papanas N. COVID-19 and Diabetes Mellitus: ' "May Old Anti-diabetic Agents Become the New Philosopher's Stone? " 'Diabetes Ther. 2020 May;11(6):1–3.', 'DOI': '10.1007/s13300-020-00830-0'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_034', 'doi-asserted-by': 'crossref', 'unstructured': 'Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, ' 'et al. Observational Study of Metformin and Risk of Mortality in ' 'Patients Hospitalized with Covid-19. medRxiv. 2020. ' 'https://doi.org/10.1101/2020.06.19.20135095.', 'DOI': '10.1101/2020.06.19.20135095'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_035', 'doi-asserted-by': 'crossref', 'unstructured': 'Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: A possible role ' 'beyond diabetes. Diabetes Res Clin Pract. 2020 Jun;164:108183.', 'DOI': '10.1016/j.diabres.2020.108183'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_036', 'doi-asserted-by': 'crossref', 'unstructured': 'Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. ' 'Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of ' 'the Renin-Angiotensin System: Celebrating the 20th Anniversary of the ' 'Discovery of ACE2. Circ Res. 2020 May;126(10):1456–74.', 'DOI': '10.1161/CIRCRESAHA.120.317015'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_037', 'doi-asserted-by': 'crossref', 'unstructured': 'Prattichizzo F, Giuliani A, Mensà E, Sabbatinelli J, De Nigris V, Rippo ' 'MR, et al. Pleiotropic effects of metformin: shaping the microbiome to ' 'manage type 2 diabetes and postpone ageing. Ageing Res Rev. 2018 ' 'Dec;48:87–98.', 'DOI': '10.1016/j.arr.2018.10.003'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_038', 'doi-asserted-by': 'crossref', 'unstructured': 'Ling Y, van Herpt TT, van Hoek M, Dehghan A, Hofman A, Uitterlinden AG, ' 'et al. A genetic variant in SLC6A20 is associated with Type 2 diabetes ' 'in white-European and Chinese populations. Diabet Med. 2014 ' 'Nov;31(11):1350–6.', 'DOI': '10.1111/dme.12528'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_039', 'doi-asserted-by': 'crossref', 'unstructured': 'Gemmati D, Tisato V. Genetic Hypothesis and Pharmacogenetics Side of ' 'Renin-Angiotensin-System in COVID-19. Genes (Basel). 2020 ' 'Sep;11(9):E1044.', 'DOI': '10.3390/genes11091044'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_040', 'doi-asserted-by': 'crossref', 'unstructured': 'Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting ' 'enzyme inhibitors or angiotensin receptor blockers for prevention of ' 'type 2 diabetes: a meta-analysis of randomized clinical trials. J Am ' 'Coll Cardiol. 2005 Sep;46(5):821–6.', 'DOI': '10.1016/j.jacc.2005.05.051'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_041', 'doi-asserted-by': 'crossref', 'unstructured': 'Niklason A, Hedner T, Niskanen L, Lanke J; Captopril Prevention Project ' 'Study Group. Development of diabetes is retarded by ACE inhibition in ' 'hypertensive patients—a subanalysis of the Captopril Prevention Project ' '(CAPPP). J Hypertens. 2004 Mar;22(3):645–52.', 'DOI': '10.1097/00004872-200403000-00029'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_042', 'doi-asserted-by': 'crossref', 'unstructured': 'Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et ' 'al.; HOPE Study Investigators. Ramipril and the development of diabetes. ' 'JAMA. 2001 Oct;286(15):1882–5.', 'DOI': '10.1001/jama.286.15.1882'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_043', 'doi-asserted-by': 'crossref', 'unstructured': 'Cheng Q, Shah N, Bröer A, Fairweather S, Jiang Y, Schmoll D, et al. ' 'Identification of novel inhibitors of the amino acid transporter B0 AT1 ' '(SLC6A19), a potential target to induce protein restriction and to treat ' 'type 2 diabetes. Br J Pharmacol. 2017 Mar;174(6):468–82.', 'DOI': '10.1111/bph.13711'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_044', 'doi-asserted-by': 'crossref', 'unstructured': 'Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, Aslam S, et al. ' 'Metabolomics reveals attenuation of the SLC6A20 kidney transporter in ' 'nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol ' 'Chem. 2011 Jun;286(22):19511–22.', 'DOI': '10.1074/jbc.M111.221739'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_045', 'doi-asserted-by': 'crossref', 'unstructured': 'Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased ' 'glomerular and tubular expression of ACE2 in patients with type 2 ' 'diabetes and kidney disease. Kidney Int. 2008 Dec;74(12):1610–6.', 'DOI': '10.1038/ki.2008.497'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_046', 'doi-asserted-by': 'crossref', 'unstructured': 'Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, et al. ' 'Expression of ACE and ACE2 in individuals with diabetic kidney disease ' 'and healthy controls. Am J Kidney Dis. 2008 Apr;51(4):613–23.', 'DOI': '10.1053/j.ajkd.2007.11.022'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_047', 'doi-asserted-by': 'crossref', 'unstructured': 'Pal R, Bhadada SK. COVID-19 and diabetes mellitus: an unholy interaction ' 'of two pandemics. Diabetes Metab Syndr. 2020 Jul–Aug;14(4):513–7.', 'DOI': '10.1016/j.dsx.2020.04.049'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_048', 'doi-asserted-by': 'crossref', 'unstructured': 'Lu CL, Wang Y, Yuan L, Li Y, Li XY. The angiotensin-converting enzyme ' '2/angiotensin (1–7)/Mas axis protects the function of pancreatic β cells ' 'by improving the function of islet microvascular endothelial cells. Int ' 'J Mol Med. 2014 Nov;34(5):1293–300.', 'DOI': '10.3892/ijmm.2014.1917'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_049', 'doi-asserted-by': 'crossref', 'unstructured': 'Cao X, Yang FY, Xin Z, Xie RR, Yang JK. The ACE2/Ang-(1–7)/Mas axis can ' 'inhibit hepatic insulin resistance. Mol Cell Endocrinol. 2014 ' 'Aug;393(1–2):30–8.', 'DOI': '10.1016/j.mce.2014.05.024'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_050', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhong JC, Yu XY, Lin QX, Li XH, Huang XZ, Xiao DZ, et al. Enhanced ' 'angiotensin converting enzyme 2 regulates the insulin/Akt signalling ' 'pathway by blockade of macrophage migration inhibitory factor ' 'expression. Br J Pharmacol. 2008 Jan;153(1):66–74.', 'DOI': '10.1038/sj.bjp.0707482'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_051', 'doi-asserted-by': 'crossref', 'unstructured': 'Ilias I, Zabuliene L. Hyperglycemia and the novel Covid-19 infection: ' 'possible pathophysiologic mechanisms. Med Hypotheses. 2020 ' 'Jun;139:109699.', 'DOI': '10.1016/j.mehy.2020.109699'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_052', 'doi-asserted-by': 'crossref', 'unstructured': 'Singer D, Camargo SM, Ramadan T, Schäfer M, Mariotta L, Herzog B, et al. ' 'Defective intestinal amino acid absorption in Ace2 null mice. Am J ' 'Physiol Gastrointest Liver Physiol. 2012 Sep;303(6):G686–95.', 'DOI': '10.1152/ajpgi.00140.2012'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_053', 'doi-asserted-by': 'crossref', 'unstructured': 'Li CY. Can Glycine Mitigate COVID-19 Associated Tissue Damage and ' 'Cytokine Storm? Radiat Res. 2020 Sep;194(3):199–201.', 'DOI': '10.1667/RADE-20-00146.1'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_054', 'doi-asserted-by': 'crossref', 'unstructured': 'Shan Q, Haddrill JL, Lynch JW. Ivermectin, an unconventional agonist of ' 'the glycine receptor chloride channel. J Biol Chem. 2001 ' 'Apr;276(16):12556–64.', 'DOI': '10.1074/jbc.M011264200'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_055', 'doi-asserted-by': 'crossref', 'unstructured': 'Lynagh T, Webb TI, Dixon CL, Cromer BA, Lynch JW. Molecular determinants ' 'of ivermectin sensitivity at the glycine receptor chloride channel. J ' 'Biol Chem. 2011 Dec;286(51):43913–24.', 'DOI': '10.1074/jbc.M111.262634'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_056', 'doi-asserted-by': 'crossref', 'unstructured': 'Chosidow O, Bernigaud C, Guillemot D, Giraudeau B, Lespine A, Changeux ' 'JP, et al. Ivermectin as a potential treatment for COVID-19? PLoS Negl ' 'Trop Dis. 2021 Jun;15(6):e0009446.', 'DOI': '10.1371/journal.pntd.0009446'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_057', 'doi-asserted-by': 'crossref', 'unstructured': 'Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ' 'ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral ' 'Res. 2020 Jun;178:104787.', 'DOI': '10.1016/j.antiviral.2020.104787'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_058', 'doi-asserted-by': 'crossref', 'unstructured': 'Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. ' 'Ivermectin for Prevention and Treatment of COVID-19 Infection: A ' 'Systematic Review, Meta-analysis, and Trial Sequential Analysis to ' 'Inform Clinical Guidelines. Am J Ther. 2021 Jun;28(4):e434–60.', 'DOI': '10.1097/MJT.0000000000001442'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_059', 'unstructured': 'Analysis C. Ivermectin for COVID-19: real-time meta analysis of 64 ' 'studies. 2021.'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_060', 'doi-asserted-by': 'crossref', 'unstructured': 'Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging ' 'Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and ' 'Treatment of COVID-19. Am J Ther. 2021 Apr;28(3):e299–318.', 'DOI': '10.1097/MJT.0000000000001377'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_061', 'doi-asserted-by': 'crossref', 'unstructured': 'Santin AD, Scheim DE, McCullough PA, Yagisawa M, Borody TJ. Ivermectin: ' 'a multifaceted drug of Nobel prize-honoured distinction with indicated ' 'efficacy against a new global scourge, COVID-19. New Microbes New ' 'Infect. 2021 Aug;43:100924.', 'DOI': '10.1016/j.nmni.2021.100924'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_062', 'unstructured': 'Yagisawa M. FPJ, Hanaki H., Omura S. . Global trends in clinical studies ' 'of ivermectin in COVID-19. Japanese J Antib. 2021;74(1).'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_063', 'doi-asserted-by': 'crossref', 'unstructured': 'Cobos-Campos R, Apiñaniz A, Parraza N, Cordero J, García S, Orruño E. ' 'Potential use of ivermectin for the treatment and prophylaxis of ' 'SARS-CoV-2 infection. Curr Res Transl Med. 2021 Oct;69(4):103309.', 'DOI': '10.1016/j.retram.2021.103309'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_064', 'doi-asserted-by': 'crossref', 'unstructured': 'Cruciani M, Pati I, Masiello F, Malena M, Pupella S, De Angelis V. ' 'Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic ' 'Review and Meta-Analysis. Diagnostics (Basel). 2021 Sep;11(9):1645.', 'DOI': '10.3390/diagnostics11091645'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_065', 'doi-asserted-by': 'crossref', 'unstructured': 'Deng J, Zhou F, Ali S, Heybati K, Hou W, Huang E, et al. Efficacy and ' 'safety of ivermectin for the treatment of COVID-19: A systematic review ' 'and meta-analysis. QJM. 2021 Sep;hcab247. ' 'https://doi.org/10.1093/qjmed/hcab247.', 'DOI': '10.1093/qjmed/hcab247'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_066', 'doi-asserted-by': 'crossref', 'unstructured': 'Hagiya H, Otsuka F. Ivermectin for Coronavirus Disease 2019: Yet to Be ' 'Well Evaluated Before Clinical Use. Clin Ther. 2021 Sep;43(9):1622–3.', 'DOI': '10.1016/j.clinthera.2021.07.007'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_067', 'doi-asserted-by': 'crossref', 'unstructured': 'Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, et al. ' 'Ivermectin for preventing and treating COVID-19. Cochrane Database Syst ' 'Rev. 2021 Jul;7:CD015017.', 'DOI': '10.1002/14651858.CD015017'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_068', 'doi-asserted-by': 'crossref', 'unstructured': 'Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral ' 'effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020 ' 'Sep;73(9):593–602.', 'DOI': '10.1038/s41429-020-0336-z'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_069', 'unstructured': 'World Health Organization. Geneva S. 22nd Model List of Essential ' 'Medicines. 2021.'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_070', 'doi-asserted-by': 'crossref', 'unstructured': 'Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use ' 'perspective. Proc Jpn Acad, Ser B, Phys Biol Sci. 2011;87(2):13–28.', 'DOI': '10.2183/pjab.87.13'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_071', 'doi-asserted-by': 'crossref', 'unstructured': 'Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob ' 'Agents. 2008 Feb;31(2):91–8.', 'DOI': '10.1016/j.ijantimicag.2007.08.023'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_072', 'doi-asserted-by': 'crossref', 'unstructured': 'Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus ' 'main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. ' 'Science. 2003 Jun;300(5626):1763–7.', 'DOI': '10.1126/science.1085658'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_073', 'doi-asserted-by': 'crossref', 'unstructured': 'Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MC, et al. ' 'Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as ' 'potential anti-SARS-CoV-2 agents. Commun Biol. 2021 Jan;4(1):93.', 'DOI': '10.1038/s42003-020-01577-x'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_074', 'doi-asserted-by': 'crossref', 'unstructured': 'Lehrer S, Rheinstein PH. Ivermectin Docks to the SARS-CoV-2 Spike ' 'Receptor-binding Domain Attached to ACE2. In Vivo. 2020 ' 'Sep–Oct;34(5):3023–6.', 'DOI': '10.21873/invivo.12134'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_075', 'unstructured': 'Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 Years of ' 'Clinical Experience With Ivermectin: An Overview of Safety for an ' 'Increasing Number of Indications. J Drugs Dermatol. 2016 ' 'Mar;15(3):325–32.'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_076', 'doi-asserted-by': 'crossref', 'unstructured': 'DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically ' 'useful anti-inflammatory agent for late-stage COVID-19. Open Heart. 2020 ' 'Sep;7(2):e001350.', 'DOI': '10.1136/openhrt-2020-001350'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_077', 'doi-asserted-by': 'crossref', 'unstructured': 'DiNicolantonio JJ, Barroso-Aranda J, McCarty MF. Anti-inflammatory ' 'activity of ivermectin in late-stage COVID-19 may reflect activation of ' 'systemic glycine receptors. Open Heart. 2021 Apr;8(1):e001655.', 'DOI': '10.1136/openhrt-2021-001655'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_078', 'doi-asserted-by': 'crossref', 'unstructured': 'Bukanova JV, Solntseva EI, Kondratenko RV, Skrebitsky VG. Antiviral Drug ' 'Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride ' 'Current in Rat Hippocampal Neurons. Bull Exp Biol Med. 2021 ' 'Mar;170(5):649–53.', 'DOI': '10.1007/s10517-021-05125-3'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_079', 'doi-asserted-by': 'crossref', 'unstructured': 'White PJ, McGarrah RW, Herman MA, Bain JR, Shah SH, Newgard CB. Insulin ' 'action, type 2 diabetes, and branched-chain amino acids: A two-way ' 'street. Mol Metab. 2021 Oct;52:101261.', 'DOI': '10.1016/j.molmet.2021.101261'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_080', 'doi-asserted-by': 'crossref', 'unstructured': 'Felig P, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin ' 'secretion in obesity. N Engl J Med. 1969 Oct;281(15):811–6.', 'DOI': '10.1056/NEJM196910092811503'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_081', 'doi-asserted-by': 'crossref', 'unstructured': 'Palmer ND, Stevens RD, Antinozzi PA, Anderson A, Bergman RN, Wagenknecht ' 'LE, et al. Metabolomic profile associated with insulin resistance and ' 'conversion to diabetes in the Insulin Resistance Atherosclerosis Study. ' 'J Clin Endocrinol Metab. 2015 Mar;100(3):E463–8.', 'DOI': '10.1210/jc.2014-2357'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_082', 'doi-asserted-by': 'crossref', 'unstructured': 'Adeva-Andany M, Souto-Adeva G, Ameneiros-Rodríguez E, ' 'Fernández-Fernández C, Donapetry-García C, Domínguez-Montero A. Insulin ' 'resistance and glycine metabolism in humans. Amino Acids. 2018 ' 'Jan;50(1):11–27.', 'DOI': '10.1007/s00726-017-2508-0'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_083', 'doi-asserted-by': 'crossref', 'unstructured': 'Irving BA, Carter RE, Soop M, Weymiller A, Syed H, Karakelides H, et al. ' 'Effect of insulin sensitizer therapy on amino acids and their ' 'metabolites. Metabolism. 2015 Jun;64(6):720–8.', 'DOI': '10.1016/j.metabol.2015.01.008'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_084', 'doi-asserted-by': 'crossref', 'unstructured': 'Qi W, Clark JM, Suvorov A, Park Y. Ivermectin decreases triglyceride ' 'accumulation by inhibiting adipogenesis of 3T3-L1 preadipocytes. Food ' 'Chem Toxicol. 2019 Sep;131:110576.', 'DOI': '10.1016/j.fct.2019.110576'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_085', 'doi-asserted-by': 'crossref', 'unstructured': 'Sachdeva S, Desai R, Gupta U, Prakash A, Jain A, Aggarwal A. Admission ' 'Hyperglycemia in Non-diabetics Predicts Mortality and Disease Severity ' 'in COVID-19: a Pooled Analysis and Meta-summary of Literature. SN Compr ' 'Clin Med. 2020 Oct;2(11):1–6.', 'DOI': '10.1007/s42399-020-00575-8'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_086', 'doi-asserted-by': 'crossref', 'unstructured': 'Ilias I, Diamantopoulos A, Pratikaki M, Botoula E, Jahaj E, Athanasiou ' 'N, et al. Glycemia, Beta-Cell Function and Sensitivity to Insulin in ' 'Mildly to Critically Ill Covid-19 Patients. Medicina (Kaunas). 2021 ' 'Jan;57(1):68.', 'DOI': '10.3390/medicina57010068'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_087', 'doi-asserted-by': 'crossref', 'unstructured': 'Jafar N, Edriss H, Nugent K. The Effect of Short-Term Hyperglycemia on ' 'the Innate Immune System. Am J Med Sci. 2016 Feb;351(2):201–11.', 'DOI': '10.1016/j.amjms.2015.11.011'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_088', 'doi-asserted-by': 'crossref', 'unstructured': 'Shao S, Yang Q, Pan R, Yu X, Chen Y. Interaction of Severe Acute ' 'Respiratory Syndrome Coronavirus 2 and Diabetes. Front Endocrinol ' '(Lausanne). 2021 Oct;12:731974.', 'DOI': '10.3389/fendo.2021.731974'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_089', 'doi-asserted-by': 'crossref', 'unstructured': 'Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature ' 'unleashed. Nat Rev Immunol. 2020 Jul;20(7):389–91.', 'DOI': '10.1038/s41577-020-0343-0'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_090', 'doi-asserted-by': 'crossref', 'unstructured': 'Burgos-Morón E, Abad-Jiménez Z, Marañón AM, Iannantuoni F, ' 'Escribano-López I, López-Domènech S, et al. Relationship Between ' 'Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The ' 'Battle Continues. J Clin Med. 2019 Sep;8(9):E1385.', 'DOI': '10.3390/jcm8091385'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_091', 'doi-asserted-by': 'crossref', 'unstructured': 'Lumpuy-Castillo J, Lorenzo-Almorós A, Pello-Lázaro AM, Sánchez-Ferrer C, ' 'Egido J, Tuñón J, et al. Cardiovascular Damage in COVID-19: Therapeutic ' 'Approaches Targeting the Renin-Angiotensin-Aldosterone System. Int J Mol ' 'Sci. 2020 Sep;21(18):E6471.', 'DOI': '10.3390/ijms21186471'}, { 'key': '2021123018400923816_j_bmc-2021-0017_ref_092', 'unstructured': 'Bălută M, Vintilă V, Vintilă M. Renin-Angiotensin-Aldosterone system ' 'inhibition in prevention of diabetes mellitus. Rom J Intern Med. ' '2004;42(2):277–88.'}], 'container-title': ['Biomolecular Concepts'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.degruyter.com/document/doi/10.1515/bmc-2021-0017/xml', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.degruyter.com/document/doi/10.1515/bmc-2021-0017/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 12, 30]], 'date-time': '2021-12-30T18:41:53Z', 'timestamp': 1640889713000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1, 1]]}, 'references-count': 92, 'journal-issue': { 'issue': '1', 'published-online': {'date-parts': [[2021, 2, 2]]}, 'published-print': {'date-parts': [[2021, 1, 1]]}}, 'alternative-id': ['10.1515/bmc-2021-0017'], 'URL': 'http://dx.doi.org/10.1515/bmc-2021-0017', 'relation': {}, 'ISSN': ['1868-503X', '1868-5021'], 'issn-type': [{'value': '1868-503X', 'type': 'electronic'}, {'value': '1868-5021', 'type': 'print'}], 'subject': [ 'Cellular and Molecular Neuroscience', 'General Biochemistry, Genetics and Molecular Biology', 'General Medicine'], 'published': {'date-parts': [[2021, 1, 1]]}}